ES2114209T3 - Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s. - Google Patents

Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s.

Info

Publication number
ES2114209T3
ES2114209T3 ES94922812T ES94922812T ES2114209T3 ES 2114209 T3 ES2114209 T3 ES 2114209T3 ES 94922812 T ES94922812 T ES 94922812T ES 94922812 T ES94922812 T ES 94922812T ES 2114209 T3 ES2114209 T3 ES 2114209T3
Authority
ES
Spain
Prior art keywords
radionuclid
hydrazino
chelators
configuration
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94922812T
Other languages
English (en)
Inventor
Alfred Pollak
Robert A Kirby
Robert Dufault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resolution Pharmaceuticals Inc
Original Assignee
Resolution Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolution Pharmaceuticals Inc filed Critical Resolution Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2114209T3 publication Critical patent/ES2114209T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transmitters (AREA)
  • Transceivers (AREA)
  • Peptides Or Proteins (AREA)
  • Lock And Its Accessories (AREA)

Abstract

SE PROPORCIONAN COMPUESTOS DE QUELACION DE RADIONUCLIDO PARA CONJUGACION DE MOLECULAS DIANA COMO PROTEINAS, PEPTIDOS O ANTICUERPOS. LAS MOLECULAS DIANA ETIQUETADAS RESULTANTES PUEDEN SER UTILIZADAS EN DIAGNOSIS Y TERAPIA.
ES94922812T 1993-07-19 1994-07-18 Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s. Expired - Lifetime ES2114209T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9291193A 1993-07-19 1993-07-19

Publications (1)

Publication Number Publication Date
ES2114209T3 true ES2114209T3 (es) 1998-05-16

Family

ID=22235766

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94922812T Expired - Lifetime ES2114209T3 (es) 1993-07-19 1994-07-18 Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s.

Country Status (11)

Country Link
US (1) US5659041A (es)
EP (1) EP0710228B1 (es)
JP (1) JPH09500140A (es)
AT (1) ATE162524T1 (es)
AU (1) AU7261994A (es)
CA (1) CA2167167A1 (es)
DE (1) DE69408145T2 (es)
DK (1) DK0710228T3 (es)
ES (1) ES2114209T3 (es)
GR (1) GR3026658T3 (es)
WO (1) WO1995003280A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5569745A (en) * 1994-02-25 1996-10-29 Resolution Pharmaceuticals Inc. Peptide-Chelator conjugates
US5662885A (en) * 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
US5804158A (en) * 1995-05-31 1998-09-08 Resolution Pharmaceuticals Inc. Sequestered imaging agents
US6027711A (en) * 1995-06-07 2000-02-22 Rhomed Incorporated Structurally determined metallo-constructs and applications
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
DE19536781A1 (de) * 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope
DE19536785A1 (de) * 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ S¶2¶NY für radioaktive Isotope
AU2323197A (en) * 1996-03-13 1997-10-01 Du Pont Pharmaceuticals Company New ternary radiopharmaceutical complexes
AU4753997A (en) * 1996-10-16 1998-05-11 Burnham Institute, The Magnetic resonance imaging of thrombi
US7060251B1 (en) 1997-09-08 2006-06-13 The General Hospital Corporation Imaging agents for early detection and monitoring of cardiovascular plaque
WO1999012579A1 (en) * 1997-09-08 1999-03-18 The General Hospital Corporation Imaging agents for early detection and monitoring of cardiovascular plaque
CA2320339A1 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6524553B2 (en) * 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
EP1068224B1 (en) 1998-03-31 2005-05-11 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
AU3119199A (en) 1998-04-03 1999-10-25 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer
US6511649B1 (en) * 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
EP1140204A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7320784B1 (en) 1999-02-17 2008-01-22 Bracco Imaging S.P.A. Immobilized labeling compounds and methods
US6409987B1 (en) 1999-04-07 2002-06-25 Intimax Corporation Targeted agents useful for diagnostic and therapeutic applications
WO2001039664A1 (en) * 1999-12-02 2001-06-07 The General Hospital Corporation Method and apparatus for measuring indices of brain activity
US6907280B2 (en) * 1999-12-02 2005-06-14 The General Hospital Corporation Method and apparatus for objectively measuring pain, pain treatment and other related techniques
US7109167B2 (en) * 2000-06-02 2006-09-19 Bracco International B.V. Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US8263739B2 (en) * 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US7311893B2 (en) * 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
JP4689803B2 (ja) * 2000-09-11 2011-05-25 住友化学株式会社 （２ｓ，４ｓ）−ｎ，ｎ−ジメチル−１−アリルオキシカルボニル−４−ベンゾイルチオ−２−ピロリジンカルボキサミドの製造方法
GB0105224D0 (en) * 2001-03-02 2001-04-18 Nycomed Amersham Plc Improved peptide-chelate conjugates
US20070021345A1 (en) * 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
AU2003207973A1 (en) * 2002-01-31 2003-09-02 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
ES2398393T3 (es) 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) * 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
EP1663199B1 (en) 2003-09-25 2013-04-03 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1781310B1 (en) * 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
WO2006027780A2 (en) * 2004-09-08 2006-03-16 Ramot At Tel Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
PT1737889E (pt) 2004-10-19 2010-12-13 Lonza Ag Método para síntese de péptidos em fase sólida
JP2008527563A (ja) * 2005-01-16 2008-07-24 ズランゴー リミテッド アイコニック通信
WO2006075335A2 (en) * 2005-01-16 2006-07-20 Zlango Ltd. Communications network system and methods for using same
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
EP1977312A2 (en) 2006-01-16 2008-10-08 Zlango Ltd. Iconic communication
EP1982450A2 (en) * 2006-01-16 2008-10-22 Zlango Ltd. Communications network system and methods for using same
CN101558081B (zh) 2006-12-11 2014-08-20 伯拉考成像股份公司 用于诊断和治疗应用的纤维蛋白结合肽缀合体
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
TW201225972A (en) 2010-11-15 2012-07-01 Univ Ramot Dipeptide analogs for treating conditions associated with amyloid fibril formation
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
EP3322716B1 (en) 2015-07-15 2025-02-12 California Institute of Technology Il-17f-specific capture agents and methods of using
WO2017137477A1 (en) 2016-02-09 2017-08-17 Bracco Suisse Sa A recombinant chimeric protein for selectins targeting
EP3440101B1 (en) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
EP3535278A4 (en) 2016-11-01 2020-06-24 Ohio State Innovation Foundation METHOD FOR IODING BIOMOLECULES
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
WO2019241851A1 (en) * 2018-06-22 2019-12-26 La Trobe University Inhibitors of lysine biosynthesis via the diaminopimelate pathway
WO2020097531A1 (en) 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
CA3227425A1 (en) 2021-07-26 2023-02-02 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4980147A (en) * 1984-06-25 1990-12-25 University Of Utah Research Foundation Radiolabeled technetium chelates for use in renal function determinations
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5037630A (en) * 1985-01-14 1991-08-06 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5120526A (en) * 1985-01-14 1992-06-09 Neorx Corporation Method of producing metal radionuclide labeled proteins for diagnosis and therapy
US5175343A (en) * 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5187264A (en) * 1986-05-28 1993-02-16 Mallinckrodt Medical, Inc. Technetium chelates to be used for determining the renal function
ATE52516T1 (de) * 1986-05-28 1990-05-15 Mallinckrodt Inc Technetiumchelate fuer die bestimmung der nierenfunktion.
US5082930A (en) * 1986-05-29 1992-01-21 Mallinckrodt Medical, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US5091514A (en) * 1987-03-26 1992-02-25 Neorx Corporation Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
US4965392A (en) * 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
DE68923274T2 (de) * 1988-02-09 1995-11-09 Mallinckrodt Inc Verfahren zur herstellung eines mit metall-radionuklid-markierten proteins.
US5202451A (en) * 1988-02-17 1993-04-13 Neorx Corporation Anchimeric radiometal chelating compounds
CA1340899C (en) * 1988-03-09 2000-02-15 Andre Bardy Procede de preparation de complexes nitruro 99m tc, 186 re ou 188 re utilisables comme produits radiopharmaceutiques
US5089249A (en) * 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
WO1990006323A2 (en) * 1988-11-29 1990-06-14 Centocor, Inc. Chimeric proteins incorporating a metal binding protein
IL93432A (en) * 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules and such conjugates labelled with metal ions
US5196515A (en) * 1989-03-17 1993-03-23 The Johns Hopkins University Thiolactone bifunctional chelating agents for diagnostic and therapeutic products
US5095111A (en) * 1989-03-17 1992-03-10 The John Hopkins University Thiolactone bifunctional chelating agents for diagnostic and therapeutic products
US5175257A (en) * 1989-12-29 1992-12-29 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
US5112953A (en) * 1989-12-29 1992-05-12 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
WO1991016076A1 (en) * 1990-04-17 1991-10-31 Mallinckrodt Medical, Inc. Method and kit for preparing technetium-99m complexes
AU9172191A (en) * 1990-12-12 1992-07-08 Mallinckrodt Medical, Inc. Method of radioactive labelling of blood cells and kit therefor
US5243073A (en) * 1990-12-14 1993-09-07 Mallinckrodt Medical, Inc. Hexadentate ligands useful in radiographic imaging agents
US5908931A (en) * 1990-12-14 1999-06-01 Mallinckrodt Inc. Preorganized hexadentate ligands useful in radiographic imaging agents
US5112594A (en) * 1991-04-04 1992-05-12 Mallinckrodt Medical, Inc. Kit for preparing a technetium-99m myocardial imaging agent
US5112595A (en) * 1990-12-21 1992-05-12 Mallinckrodt Medical, Inc. 99MTC(III) myocardial imaging agents and method of use
DE69230525T2 (de) * 1991-02-08 2000-06-21 Diatide, Inc. Technetium-99m markierte Polypeptide zur Bildformung
WO1992019235A2 (en) * 1991-05-01 1992-11-12 The Curators Of The University Of Missouri Multifunctional ligand for use as a diagnostic or therapeutic pharmaceutical
AU1995392A (en) * 1991-05-08 1992-12-21 Mallinckrodt Medical, Inc. Technetium chelates to be used for determining the renal function
WO1992021383A1 (en) * 1991-06-03 1992-12-10 Mallinckrodt Medical, Inc. Radiolabelled somatostatin derivatives, their preparation and use
AU670029B2 (en) * 1991-08-05 1996-07-04 Mallinckrodt Medical, Inc. Heavy metal clusters for use as imaging agents

Also Published As

Publication number Publication date
ATE162524T1 (de) 1998-02-15
EP0710228B1 (en) 1998-01-21
US5659041A (en) 1997-08-19
DK0710228T3 (da) 1998-09-21
CA2167167A1 (en) 1995-02-02
GR3026658T3 (en) 1998-07-31
JPH09500140A (ja) 1997-01-07
DE69408145D1 (de) 1998-02-26
WO1995003280A1 (en) 1995-02-02
DE69408145T2 (de) 1998-09-03
EP0710228A1 (en) 1996-05-08
AU7261994A (en) 1995-02-20

Similar Documents

Publication Publication Date Title
ES2114209T3 (es) Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s.
DE69417426D1 (de) N2s2-chelatoren des hydrazino-typs
DE69434384D1 (de) Metalkomplexbildner
NO304552B1 (no) Kompleksforbindelser, konjugater, farmas°ytiske preparater inneholdende slike og forbindelser
ATE58297T1 (de) Kupplungsmittel zum radiomarkieren von proteinen.
FI956019A7 (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA -C-klooni-10:n kanssa, ja niiden käyttö
EP0724456A4 (en) ANTIBODIES AGAINST CD40
NO301829B1 (no) 2-pyridylmetylenpolyazamakrocyklo-fosfonsyrer, komplekser og farmasöytiske preparater basert på disse
ATE544776T1 (de) Chimäre dna-bindeproteine
DK0570493T3 (da) Technetium-99m-mærkede polypeptider til billeddannelse.
ATE178597T1 (de) Biologisch nützliche konjugate
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
FI943724A0 (fi) Stabiloidut radiofarmaseuttiset pakkaukset
ES2152251T3 (es) Variantes del dominio lectina de la selectina.
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
DE69230798D1 (de) Rekombinante immuntoxine
DE69133068D1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
NO971059D0 (no) Modifiserte human-C3-proteiner
DE69127334D1 (de) Verabreichung von Mitteln
ATE331728T1 (de) Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie
NO953865L (no) Bifunksjonelle chelatorer og deres anvendelse i radiofarmasöytiske midler
ES2173862T3 (es) Ligandos de aminocarboxilato que tienen restos amidicos aromaticos sustituidos.
ES2150421T3 (es) Nuevos conjugados, consistentes en una glicoproteina y una sustancia que se fija a acidos nucleicos.
NO954442D0 (no) Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler, og fremgangsmåter for deres fremstilling
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 710228

Country of ref document: ES